ABOUT US

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease.

Wilson Therapeutics AB was founded in 2012 and is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.